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Prostate cancer is a commonly diagnosed cancer in men. The ethanolic extract of propolis (EEP) and its phenolic compounds
possess immunomodulatory, chemopreventive and antitumor eﬀects. Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL/APO2L) is a naturally occurring anticancer agent that preferentially induces apoptosis in cancer cells and is not toxic
to normal cells. We examined the cytotoxic and apoptotic eﬀects of EEP and phenolic compounds isolated from propolis in
combination with TRAIL on two prostate cancer cell lines, hormone-sensitivity LNCaP and hormone-refractory DU145. The
cytotoxicity was evaluated by MTT and LDH assays. The apoptosis was determined using ﬂow cytometry with annexin V-
FITC/propidium iodide. The prostate cancer cell lines were proved to be resistant to TRAIL-induced apoptosis. Our study
demonstrated that EEP and its components signiﬁcantlysensitize to TRAIL-induced death in prostate cancer cells. The percentage
oftheapoptoticcells aftercotreatment with50μgmL −1 EEP and 100ngmL−1 TRAILincreased to74.9 ±0.7%forLNCaPand57.4
± 0.7% for DU145 cells. The strongestcytotoxic eﬀect on LNCaP cells was exhibited by apigenin, kaempferid,galangin and caﬀeic
acid phenylethyl ester (CAPE) in combination with TRAIL (53.51 ± 0.68–66.06 ± 0.62% death cells). In this work, we showed
that EEP markedly augmented TRAIL-mediated apoptosis in prostate cancer cells and suggested the signiﬁcantrole of propolis in
chemoprevention of prostate cancer.
1.Introduction
Prostate cancer is a commonly diagnosed cancer in men, and
it is the second leading cause of death due to cancer in men
in the European Union and in the USA. The rate of prostate
cancer among all new cancer cases has been estimated
at 12% in the EU and 29% in the USA. The molecular
mechanisms responsible for the initiation and progression
of prostate cancer have not been elucidated, and the only
established risk factors for this disease include age, ethnic
group, diet and hereditary susceptibility [1]. Prostate cancer
behavior is mostly unpredictable; however, its longer time of
progression to malignancy and metastasis provides broader
possibilities for its managements, including the suitability
for chemopreventive intervention. Chemoprevention is a
rapidly growing area of uro-oncology, which focuses on
prevention of prostate cancer using naturally occurring or
synthetic agents [2, 3]. Many plant and animal extracts show
various biological activities, such as immunopotentiating
and antitumor properties [4–6].
Propolis (bee glue) is a resinous hive product collected
by honey bees from many plant sources. Propolis usu-
ally contains a variety of diﬀerent chemical compounds,
including phenolic acids or their esters, ﬂavonoids (ﬂavones,
ﬂavanones, ﬂavonols, dihydroﬂavonols and chalcones), ter-
penes, aromatic aldehydes and alcohols, fatty acids, stilbenes
and β-steroids [7, 8]. Propolis cannot be used in its crude
form, and so it must be puriﬁed by extraction to remove the
inert material and preserve the polyphenolic fraction. The
ethanolic extract of propolis (EEP) has attracted researchers’
interest in the last decades because of its biological and phar-
macological properties, such as immunomodulatory and
anticancer eﬀects [9–11]. Several mechanisms contribute
to the overall cancer preventive and antitumor properties
of propolis and its phenolic components. Further study
demonstrated that ﬂavonoids, phenolic acids, as well as EEP2 Evidence-Based Complementary and Alternative Medicine
inhibit the cancer cells proliferation and tumor growth,
induce cell-cycle arrest and apoptosis [10–14].
The target of much research has been on discovery
of natural and synthetic compounds that can be used in
the prevention of cancer. Epidemiological and preclinical
evidence suggest that polyphenols isolated from propolis
possess cancer chemopreventive properties [12]. Due to the
fact that propolis is a rich source of plant phenolics and
polyphenolics, it can be used as a dietary supplement in
prostate cancer prevention.
The role of host immune functions has become increas-
ingly important in our understanding of the mechanisms
involved in cancer prevention. EEP stimulated nonspeciﬁc
immunity, activated humoral immunity, and enhanced cell-
mediated immunity [10, 15]. The increase of the host
immunedefencebypropolisagainst tumorcellssuggeststhat
immunomodulatoryeﬀectsofEEPmaybeinvolvedincancer
chemoprevention.
Tumor necrosis factor-related apoptosis inducing ligand
(TRAIL), a member of TNF superfamily, selectively induces
apoptosis in cancer cells with no toxicity against normal tis-
sues. Soluble, or expressed on lymphocytes T, macrophages
and NK cells molecules, TRAIL plays an important role in
immunesurveillanceanddefencemechanisms against tumor
cells. The cytotoxic eﬀector functions of those immune cells
are important for enabling the immune system to cope
eﬃcientlywithmalignancy.TRAILinducesprogrameddeath
in various cancer cells through its interaction with the death
receptor TRAIL-R1 and/or TRAIL-R2 [16].
However, some tumor cells are resistant to TRAIL-
mediated cytotoxicity. The decreased expression of death
receptors TRAIL-R1 and TRAIL-R2 or increased expression
of antiapoptotic protein in cancer cells are involved in
TRAIL-resistance. We and others have shown that TRAIL-
resistant prostatecancercellscanbesensitizedbychemother-
apeutic agents, ionizing radiation, or dietary polyphenols
[17–19].
In this work, we investigated the apoptotic and/or
cytotoxic eﬀect of EEP and some of its phenolic derivatives
in combination with TRAIL on prostate cancer cells. We
showed for the ﬁrst time that EEP sensitizes prostate cancer
cells to TRAIL-induced apoptosis. Our results indicated
that EEP markedly augments TRAIL-mediated apoptosis
in hormone-sensitivity LNCaP and hormone-refractory
DU145 prostate cancer cells. The TRAIL-mediated cytotoxic
and apoptotic pathways may be a target of the chemopre-
ventive agents in prostate cancer cells, and the overcome of
TRAIL-resistance by propolis and its phenolic components
may be one of the mechanisms responsible for their cancer
preventive eﬀects.
2.Methods
2.1. Propolis Sample and EEP. Propolis was collected manu-
allyfrombeehiveslocatedinsouthernPoland(TheCarpathi-
ans, Nowy Sacz region) and kept desiccated pending its
processing. It was extracted in 95% (v/v) ethyl alcohol, in
a hermetically closed glass vessel for 4 days at 37◦C, under
occasional shaking. The ethanolic extract was then ﬁltered
through a Whatman ﬁlter paper no 4 and evaporated in a
rotary evaporator, under reduced pressure at 60◦C.The same
collection and extraction procedures were used throughout
all our laboratory studies [9]. EEP was dissolved in DMSO
(50mgmL−1), and the ﬁnal concentration of DMSO in the
culture medium was controlled at 0.1% (v/v).
2.2. Flavonoids and Phenolic Acids. Propolis samples from
various geographical areas contain diﬀerent compounds.
The major active components of propolis from Poland are
ﬂavonoids and phenolic acids or their esters [7]. All tested
compounds were detected in our sample of EEP as described
previously [9]. Table 1 presents the structures of compounds
found in the tested sample of EEP. Chrysin, apigenin,
acacetin, galangin, kaempferol, kaempferid, quercetin, cin-
nanic acid, o-coumaric acid, m-coumaric acid, p-coumaric
acid, caﬀeic acid and caﬀeic acid phenylethyl ester (CAPE)
were purchased from Carl Roth GmbH (Karlsruhe, Ger-
many) and Sigma Chemical Company (St Louis, MO, USA).
The reagents were dissolved in DMSO (ﬂavonoids and phe-
nolic acids—50mM) and the ﬁnal concentration of DMSO
intheculturemediumwascontrolledat0.1%(v/v).Theﬁnal
concentration of ﬂavonoids and phenolic acids was 50μM
(chrysin, 12.7μgmL −1; apigenin, 13.5μgmL −1;a c a c e t i n ,
14.2μgmL −1; galangin, 13.5μgmL −1; kaempferol, 14.3μg
mL−1; kaempferid, 15.0μgmL −1; quercetin, 15.1μgmL −1;
cinnanic acid,7.4μgmL −1;o-coumaric acid,8.2μgmL −1;m-
coumaric acid, 8.2μgmL −1; p-coumaric acid, 8.2μgmL −1;
caﬀeic acid, 9.0μgmL −1; CAPE, 14.2μgmL −1).
2.3. TRAIL. Recombinant human TRAIL was purchased
from PeproTech (Rocky Hill, NJ, USA).
2.4.ProstateCancer Cells Culture. Theexperimentswereper-
formed on two human prostate cancer cell lines: hormone-
sensitivity LNCaP cells and hormone-refractory DU145 cells
(DSMZ—German Collection of Microorganisms and Cell
Cultures, Braunschweig, Germany). The cells were grown
in monolayer cultures in RPMI 1640 medium containing
1 0 %f e t a lb o v i n es e r u m ,4 m Ml-glutamine, 100UmL−1
penicillin and 100μgmL −1 streptomycin and incubated at
37◦C in atmosphere containing 5% CO2 [19]. Reagents for
cells culture were purchased from PAA The Cell Culture
Company (Pasching, Austria).
2.5. Cytotoxicity Assay. The cytotoxicity was measured by 3-
[4, 5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium (MTT)
assay as described [19]. The LNCaP cells (2 × 105 mL−1)
and DU145 (1 × 105 mL−1) were seeded 48–24h before
the experiments onto a 96-well plate. Various combina-
tions of EEP (5–50ngmL−1) with or without TRAIL (50–
200ngmL−1), ﬂavonoids (50μM) with or without TRAIL
(100ngmL−1), and phenolic acids (50μM) with or without
TRAIL(100ngmL−1)w e r ea d d e dt ot h ec e l l s ,a n d ,a f t e r4 8h ,
the medium was removed, and 20μL of a MTT solution
prepared at 5mgmL−1 (Sigma Chemical Company, MO,
USA) were added to each well for 4h. The resulting crystalsEvidence-Based Complementary and Alternative Medicine 3
Table 1: Chemical structure of the phenolic compounds used in this study.
CH=CH-COOH
R1
R2
R3
R1 R2 R3
Cinnamic acid H H H
o-Coumaric acid OH H H
m-Coumaric acid H OH H
p-Coumaric acid H H OH
Caﬀeic acid H OH OH
Caﬀeic acid phenylethyl ester
OH
OH
O
O
O
O
R4
R5
R6
R1
R2
R3
R1 R2 R3 R4 R5 R6
Chrysin H OH H OH H H
Apigenin H OH H OH OH H
Acacetin H OH H OH OCH3 H
Galangin OH OH H OH H H
Kaempferol OH OH H OH OH H
Kaempferid OH OH H OH OCH3 H
Quercetin OH OH H OH OH OH
were dissolved in DMSO. Controls included native cells and
medium alone. The spectrophotometric absorbance of each
well was measured using a microplate reader (ELx 800,
Bio-Tek Instruments, Winooski, VT, USA) at 550nm. The
percent cytotoxicity was calculated by the formula: percent
cytotoxicity (cell death) = (1 − [absorbance of experimental
wells/absorbance of control wells]) × 100%.
2.6. Lactate Dehydrogenase Release Assay. Lactate dehydro-
genase (LDH) is a stable cytosolic enzyme that is released4 Evidence-Based Complementary and Alternative Medicine
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Figure1:InductionofcytotoxicityandapoptosisbyEEPinprostatecancercells.Thecellswereincubatedfor48hwithEEPatconcentrations
of 0–50μgmL −1. Cytotoxic activity of EEP in prostate cancer cells: (a) LNCaP and (b) DU145. The percentage of cell deaths was measured
by MTT cytotoxicity assay. EEP induced apoptosis in prostate cancer cells: (c) LNCaP and (d) DU145. Detection of apoptotic cell death
by annexin V-FITC staining using ﬂow cytometry. The values represent mean ± SD of three independent experiments performed in
quadruplicate (n = 12). All diﬀerences are statistically signiﬁcantin relation to control (P < .05).
upon membrane damage in necrotic cells. LDH activity was
measured using a commercial cytotoxicity assay kit (Roche
Diagnostics GmbH, Mannheim, Germany), in which LDH
released in culture supernatants is measured with a coupled
enzymatic assay, resulting in conversion of a tetrazolium salt
into red formazan product. The prostate cancer cells were
treated with EEP in various concentrations (5–50ngmL−1)
alone and in combination with TRAIL (50–200ngmL−1),
phenolic compounds (50μM) alone and in combination
with TRAIL (100ngmL−1) for the indicated period of
time. The sample solution (supernatant) was removed, and
LDH released from cells was measured in culture medium.
The maximal release was obtained after treating control
cells with 1% Triton X-100 (Sigma Chemical Company, St.
Louis, MO) for 10 min at room temperature [19]. The
necroticpercentage wasexpressed using theformula (sample
value/maximal release) × 100%.
2.7. Determination of Apoptotic Cell Death by Annexin
V-FITC Staining. Prostate cancer cell line LNCaP (2 ×
105 mL−1)andDU145(1 ×105 mL−1)wereseededin24-well
platesfor24–48handthenexposedtoEEPand/orTRAILfor
48h. After 48-h incubation, cancer cells were washed twice
with PBS and resuspended in 1mL of binding buﬀer. Five
hundred microliters of cell suspension were then incubated
with 5μL of annexin V-FITC and 10μL of propidium iodide
(PI) for 10 min at room temperature in the dark. Annexin V
assay was performed using the Apoptotest-FITC Kit (Dako,
Glostrup, Denmark). The population of annexin V-positive
cells was evaluated by ﬂow cytometry (BD FACScan, Becton
Dickinson Immnunocytometry Systems, San Jose, CA, USA)
[20].
2.8. Statistical Analysis. The results are expressed as mean ±
SD obtained from three separate experiments. The exper-
imental means were compared to the means of untreated
prostate cancer cells harvested parallelly, and the data were
polled for replicate experiments. Statistical signiﬁcance was
evaluated using one- and multiple-way ANOVA or Kruskal–
Wallis test followed bytheLevenepost hoc test. P-values<.05
were considered signiﬁcant.Evidence-Based Complementary and Alternative Medicine 5
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Figure 2: Induction of cytotoxicity and apoptosis by TRAIL in prostate cancer cells. The cells were incubated for 48h with TRAIL at
concentrations of 0–200ngmL−1. Cytotoxic activity of TRAIL in prostate cancer cells: (a) LNCaP and (b) DU145. The percentage of cell
deaths was measured by MTT cytotoxicity assay. TRAIL induced apoptosis in prostate cancer cells: (c) LNCaP and (d) DU145. Detection of
apoptotic cell death by annexin V-FITC staining using ﬂow cytometry. The values represent mean ± SD of three independent experiments
performed in quadruplicate (n = 12). All diﬀerences are statistically signiﬁcant in relation to control (P < .05).
3.Results
3.1. Induction of Cytotoxicity and Apoptosis by Studied Agents
on Prostate Cancer Cells
3.1.1. EEP. EEP inhibited growth and induced apoptosis in
prostate cancer cells in a dose-dependent manner. The cyto-
toxic and apoptotic eﬀects of EEP on hormone-sensitivity
LNCaPand hormone-refractory DU145prostate cancercells
are given in Figure 1. The cells were incubated with 5–
50μgmL −1 EEP for 48h. The rate of cytotoxicity upon
treatment cancer cells with 5, 25 and 50μgmL −1 EEP was
5.96 ± 0.61, 23.08 ± 0.78 and 24.83 ± 0.59% for LNCaP
cells and 4.75 ± 0.67, 8.20 ± 1.12 and 16.63 ± 0.77% for
DU145 when compared with untreated control, respectively.
The annexin V assay revealed apoptotic prostate cancer cells
exposed toEEP. Weshowed thatEEP atthe concentrationsof
5–50μgmL −1 induced 4.95 ± 0.54, 23.28 ± 0.54 and 24.66 ±
0.72% apoptosis in LNCaP cells and 5.44 ± 0.45, 8.52 ± 0.48
and 17.09 ± 0.55% apoptosis in DU145 cells.
3.1.2.TRAIL. TRAILinducedcytotoxicand apoptoticeﬀects
in a dose-dependent manner (Figure 2). We ﬁrst measured
the cytotoxic activity of TRAIL after 48-h incubation on
prostate cancer cells. The cytotoxicity of TRAIL at the
concentration of 100ngmL−1 on LNCaP cells was 15.03 ±
0.50%, and on DU145 cells 9.25 ± 0.86%. TRAIL increased
the percentage of apoptotic cells. For example, a 48-h
exposure to 100ngmL−1 TRAIL induced apoptosis of 15.46
± 0.55% LNCaP cells and 10.12 ± 0.86% of DU145 cells.
TRAIL was less active against the both prostate cancer cell
lines. We conﬁrmed that hormone-sensitivity LNCaP cells
and hormone-refractory DU145 prostate cancer cells are
resistant to TRAIL.
3.1.3. TRAIL in Combination with EEP. We investigated the
cytotoxic and apoptotic eﬀects of TRAIL in combination
with EEP on prostate cancer cells (Figures 3 and 4). Cotreat-
ment of TRAIL and EEP increased the percentage of cell
death on prostate cancer cells, compared to cytotoxicity of
TRAIL or EEP alone. The cytotoxicity after 48-h incubation
with TRAIL at the concentration of 100ngmL−1, and EEP
at the concentration of 50μgmL −1 was 73.70 ± 0.53%
for hormone-sensitivity LNCaP cells and 55.76 ± 0.72%
for hormone-refractory DU145 cells. Then, we tested the
apoptotic eﬀect of TRAIL in combination with EEP on6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Cytotoxic activity ofTRAIL in combinationwith EEP in prostatecancer cells. The cells: (a)LNCaPand (b) DU145 were incubated
for 48h with TRAIL at the concentrations of 100ngmL−1 and with EEP at concentrations of 5–50μgmL −1. The cancer cells: (c) LNCaP
and (d) DU145 were incubated for 48h with TRAIL at concentrations of 50–200ngmL−1 and EEP at the concentration of 50μgmL −1.
The percentage of cell deaths was measured by MTT cytotoxicity assay. The values represent mean ± SD of three independent experiments
performed in quadruplicate (n = 12). All diﬀerences are statistically signiﬁcant in relation to control (P < .05).
0
20
40
60
80
A
p
o
p
t
o
t
i
c
c
e
l
l
s
(
%
)
(
a
n
n
e
x
i
n
V
)
100
50
100
50
TRIAL
(ng/mL)
EEP
(µg/mL)
-
--
-
(a)
0
20
40
60
80
A
p
o
p
t
o
t
i
c
c
e
l
l
s
(
%
)
(
a
n
n
e
x
i
n
V
)
100
50
100
50
TRIAL
(ng/mL)
EEP
(µg/mL)
-
-
-
-
(b)
Figure 4:TRAIL induced apoptosisin combinationwith EEP in prostatecancer cells:(a)LNCaP and(b) DU145.Detection ofapoptotic cell
death after 48-h cotreatment with TRAIL at the concentration of 100ngmL−1 and EEP the concentration of 50μgmL −1 by annexin V-FITC
staining using ﬂow cytometry. The values represent mean ± SD of three independent experiments performed in quadruplicate (n = 12). All
diﬀerences are statistically signiﬁcantin relation to control (P < .05).
prostate cancer cells. We found that EEP strongly enhanced
TRAIL-induced apoptosis in cancer cells. The percentage
of apoptotic cells after exposure to 100ngmL−1 TRAIL in
combination with 50μgmL −1 EEP increased to 74.94 ±
0.74%forLNCaPcellsandto57.39 ±0.67%forDU145cells.
Our results indicated that EEP enhanced apoptosis inducing
potential of TRAIL in hormone-sensitivity LNCaP and
hormone-refractory DU145 prostate cancer cells. Propolis
restored sensitivity of prostate cancer cell lines to TRAIL-
induced cell death.
The necrotic cell death percentageofprostate cancercells
incubated with TRAIL and/or EEP examined by LDH test
was near 0.
The sequence of drug administration is important to
obtain maximum therapeutic beneﬁts in combined therapy.
We therefore examined whether cotreatment of prostateEvidence-Based Complementary and Alternative Medicine 7
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Figure 5: Cytotoxic activity of TRAIL in combination with EEP, after and before exposure to EEP in prostate cancer cells. (a) LNCaP and
(b) DU145 cancer cells were as follws: (1) treated with EEP in combination with TRAIL for 48h; (2) pretreated with EEP for 24h, followed
by TRAIL for another 24h; and (3) pretreated with TRAIL for 24h, followed by EEP for another 24h. The percentage of cell deaths was
measured by MTT cytotoxicity assay. The values represent mean ± SD of three independent experiments performed in quadruplicate (n =
12). All diﬀerences are statistically signiﬁcant in relation to control (P < .05).
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Figure 6: Cytotoxic activity of (a) EEP phenolic components and (b) TRAIL in combination with EEP phenolic components in prostate
cancer cells. The LNCaP cells were incubated for 48h with phenolic compounds at the concentration of 50μM with or without TRAIL at
the concentration of 100ngmL−1. The percentage of cell deaths was measured by MTT cytotoxicity assay. The values represent mean ± SD
of three independent experiments performed in quadruplicate (n = 12). All diﬀerences are statistically signiﬁcant in relation to control (P <
.05).
cancer cells with EEP and TRAIL induced greater apop-
tosis than the concurrent pretreatment with EEP followed
by TRAIL and vice versa (Figure 5). Interestingly, the
cotreatment of both prostate cancer cell lines with EEP in
combination with TRAIL induced greater apoptosis than
concurrent pretreatment or single agent alone. Reverse
sequence of treatments: pretreatment with EEP followed by
TRAILorpretreatmentwithTRAILfollowedbyEEPresulted
in signiﬁcantly lesser apoptosis than in the cotreatment with
EEP and TRAIL.
3.2. Cytotoxicity of Studied Agents in Prostate Cancer Cells
3.2.1. Phenolic Compounds Detected in Propolis. We inves-
tigated the cytotoxic eﬀect on LNCaP cells of 13 phe-
nolic components of propolis: cinnamic acid, o-coumaric8 Evidence-Based Complementary and Alternative Medicine
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Figure 7: The molecular targets of ﬂavonoidsin TRAIL apoptosis pathway and the hypothetic impact of EEP in TRAIL-mediated apoptosis
in cancer cell. TRAIL binds to death receptors, TRAIL-R1 and/or TRAIL-R2 and promotes the recruitment of adapter molecule FADD (Fas-
associated-death domain) to activate caspase-8, which trigger activation of downstream eﬀector caspases (caspase-3, -6 and -7). Caspase-8
mediated also cleavage of Bid (BH3-interacting domain death agonist). Trucated Bid called tBid translocates to the mitochondria where
it interacts with Bax (Bcl-2-associated X protein) and Bak (Bcl-2-agonist/killer), stimulating the release oh cytochrome c. Antiapoptotic
members of Bcl-2 family could inhibit cytochrome c release. Cytochrome c liberated from the mitochondria then binds to the adaptor
protein APAF-1 (apoptotic protease-activating factor-1) and procaspase-9, formingthe apoptosome and activating caspase-9, which in turn
activates executioner caspases (caspase-3, -6 and -7) leading to cell death. Caspase-9 activity is controlled by IAPs (inhibitor of apoptosis
protein) and survivin. Luteolin, apigenin, kaempferol, quercetin and baicalein increase expression of death receptor TRAIL-R2. Apigenin
activate executioner caspases and block antiapoptotic Bcl-2 action. Quercetin promotes apoptosis by inhibition of survivin.
acid, m-coumaric acid, p-coumaric acid, caﬀeic acid,
CAPE, chrysin, apigenin, acacetin, galangin, kaempferol,
kaempferid and quercetin (Figure 6(a)). The strongest cyto-
toxic activity in cancer cells was demonstrated by apigenin
(18.76 ± 0.65% cell death). Kaempferol, kaempferid and
quercetininduced few cell deaths(11.42 ± 0.68, 13.44 ± 0.44
and 13.36 ± 0.59%, respectively). The cytotoxicity of other
remaining compounds found in propolis in prostate cancer
cells was below 10%.
3.2.2. TRAIL in Combination with Phenolic Compounds
Detected in Propolis. Cytotoxic eﬀect of TRAIL in combi-
nation with phenolic acids or ﬂavonoids in LNCaP cell
line measured by MTT assay is shown in Figure 6(b).W e
tested the eﬀect of a 48-h cotreatment with TRAIL at the
concentration of 100ngmL−1 together with 13 phenolic
components of propolis at the concentration of 50μMo n
cytotoxicity of prostate cancer cells. The phenolic acids and
particularly ﬂavonoids restored TRAIL sensitivity in TRAIL-
resistant LNCaP cells. In our study, apigenin, kaempferid,
galangin and CAPE markedly augmented TRAIL mediated
cancer cell deaths (53.51 ± 0.68–66.06 ± 0.62%) and
exhibited the strongest cytotoxic eﬀect in combination with
TRAIL on LNCaP cells. The other components found in our
sample of propolis also increased the percentage of TRAIL-
induced cell deaths, compared to cytotoxicity of TRAIL
alone, but the cytotoxicity was below 50%.
The necrotic cell death percentage of LNCaP cells incu-
batedwith TRAILand/orphenoliccomponents examined by
LDH leakage was near 0.
4.Discussion
Epidemiological data support the concept that naturally
occurring anticancer agents in the human diet are safe, and
nontoxic, and they have long-lasting beneﬁcial eﬀects on
human health[12?].The potentialtargetforcomplementary
and alternative medicine (CAM) research has been on
the discovery of natural compounds that can be used in
prevention against prostate cancer.
The study by Li et al. [21] showed that propolis
inhibits cellular proliferation and induces apoptosis in
prostate cancer cells. In our investigation, we also observed
cytotoxic and apoptotic activities of EEP against hormone-
sensitivity LNCaP and hormone-refractory DU145 prostate
cancer cells. Beside antitumor eﬀect, immunomodulatory
properties of propolis have been recorded. We investi-
gated the interaction between propolis and tumor necrosisEvidence-Based Complementary and Alternative Medicine 9
factor-related apoptosis inducing ligand on prostate cancer
cells. Recombinant human TRAIL used in our study is a
soluble protein based on a natural ligand. TRAIL induces
programmed death in various cancer cells, in vitro and in
vivo[16]. However, some tumor cells are resistant to TRAIL-
mediated cytotoxicity. We and others demonstrated that
prostate cancer cell lines, LNCaP and DU145, were resistant
to TRAIL-induced apoptosis [17–19].
Our study showed the impact of propolis on the
anticancer immune defense. Propolis restores sensitivity
of tumor cells to immune eﬀectors mechanisms, such as
TRAIL-induced apoptosis in prostate cancer cells. For the
ﬁrst time, our results demonstrated that EEP markedly aug-
mented TRAIL-mediated apoptosis in hormone-sensitivity
LNCaP and hormone-refractory DU145 prostate cancer
cells. The rapid tumor growth and progression of hormone
refractory prostate canceraccountsfor most ofthe morbidity
and mortality associated with prostate cancer[1]. The exper-
imentaldataindicatedthatpropolisisapromisinganticancer
agent also for the prevention of hormone-refractory prostate
cancer.
In the ﬁeld of CAM, immunomodulation through natu-
ral or synthetic substances may be considered as an alterna-
tive for the prevention of neoplasm disease. EEP enhances
the apoptosis-inducing potential of TRAIL and sensitizes
TRAIL-resistant prostate cancer cells. Further investigations
will be required to recognize and explain the molecular
mechanisms and cellular signaling pathways by which EEP
sensitizes cancer cells to TRAIL-induced death. Moreover,
due to heterogenous complex composition of propolis, its
biological activity is variable. The presence in propolis of so
many compounds makes it diﬃcult to know and understand
the direct and indirect eﬀects of EEP upon transduction
pathwayofthesignal toTRAIL-mediatedapoptosis incancer
cells.
The ﬂavonoids and phenolic components found in
propolis are known to aﬀect the apoptosis of prostate
cancer cells and may play an important role in cancer
chemoprevention [2, 3, 22, 23]. We tested in vitro the
cytotoxicity of 13 compounds detected in our sample of
propolis against prostate cancer. The strongest cytotoxic
activity on LNCaP prostate cancer cells was demonstrated by
apigenin. Shukla and Gupta [22, 24]r e p o r t e dt h a ta p i g e n i n
in both in vitro and in vivo studies induced apoptosis in
prostate cancer.
It has been suggested that phenolic compounds isolated
from propolis induce activities of the immune system
and exert antitumor eﬀects [9–15, 21–24]. To investigate
which compounds found in propolis may be responsible
for the enhancement of the apoptosis-inducing potential
of TRAIL, we tested the cytotoxic eﬀect of its phenolic
components in combination with TRAIL on prostate cancer
cells. All detected in our EEP sample compounds used
in combination with TRAIL increased the percentage of
cell deaths compared to cytotoxicity of TRAIL alone. The
phenolic acids and particularly ﬂavonoids restored TRAIL
sensitivity in TRAIL-resistant LNCaP prostate cancer cells.
In our study, apigenin, kaempferid, galangin and CAPE
markedly augmented TRAILmediated cancercellsdeathand
exhibited the strongest cytotoxic eﬀect in combination with
TRAIL on LNCaP cells. Apigenin, kaempferid and galangin,
the compounds with the most cytotoxicactivity with TRAIL,
have three hydroxyl groups (positions 5, 7 and 3 or 4 ).
Every tested ﬂavonoid has hydroxyl groups in ﬁfth and
seventh positions. The compounds with only two hydroxyl
groups in ﬁfth and seventh positions (chrysin, acacetin),
or four (kaempferol) and ﬁve hydroxyl groups (quercetin)
showed lower cytotoxic activity with TRAIL. The presence
of hydroxyl group in position 3 (galangin versus chrysin)
decreased activity of galangin, but addition of TRAIL
changed this activity. Probably, this activity is dependent on
diﬀerent mechanisms. The position of hydroxyl groups in
ﬂavone structure and their number are very important in
reaction with reactive oxygen species as well as can inﬂuence
cytotoxic and apoptotic activities [25, 26].
In study in vitro on HeLa cell line, we conﬁrmed
that EEP sensitize cancer cells to TRAIL-induced apoptosis
and two components identiﬁed in propolis, apigenin and
CAPE, were the most potent agents inducing cell death in
combination with TRAIL in HeLa cells [20]. A similar study
with ﬂavonoids (Figure7) showed that luteolin, apigenin,
kaempferol, baicalein and quercetin synergistically induced
apoptosis with TRAIL in human malignant tumor cells [18,
27–32]. Horinaka et al. [27] reported that luteolin increased
TRAIL-induced apoptosis in HeLa cells through upregula-
tion of death receptor TRAIL-R2. In other investigation,
they also showed the enhanced apoptosis-inducing potential
of TRAIL in prostate cancer cell line DU145, leukemic cell
line Jurkat, and colon cancer cell line DLD1. The combined
use of apigenin and TRAIL caused Bcl-2-interacting domain
cleavage, activation of caspases, and increased expression
of TRAIL-R2 [18]. Yoshida et al. [28]s t a t e dt h a tT R A I L -
R2 upregulation by kaempferol augments TRAIL action
in colon cancer cells [28]. Chen et al. [29] showed that
suppression of survivin and induction of TRAIL-R2 by
quercetin contribute to sensitization of lung cancer cells
to TRAIL-induced cytotoxicity. Kim et al. [30]e x a m i n e d
the molecular mechanisms by which quercetin augments
TRAIL-mediated apoptotic death in prostate cancer cells
and conﬁrmed the ability of quercetin to downregulate
survivin expression. Taniguchi et al. [31] indicated that
baicalein increases TRAIL-R2 expression and overcomes
TRAIL resistance in prostate cancer cells.
We demonstrated for the ﬁrst time that kaempferid,
galangin and CAPE enhance the cytotoxic potential of
TRAIL in prostate cancer cells. Those polyphenols, beside
apigenin, equally ﬁrmly sensitize TRAIL-resistant LNCaP
cells. The previous study suggested that ﬂavonoids increase
expressionofTRAIL-R2[18,27–29,31].Wehypothesizethat
propolis, as one of the richest sources of ﬂavonoids, such as
apigenin, kaempferol, kaempferid, galangin, quercetin and
CAPE,caninﬂuencetheexpressionofdeathreceptorTRAIL-
R2, inhibition of antiapoptotic protein (Bcl-2, survivin), or
activation of caspases (Figure 7).
We showed that EEP and its phenolic components in
vitro augmented TRAIL mediated cell death in prostate
cancer, but further study will be required to examine the
molecular mechanisms by which EEP and its compounds act10 Evidence-Based Complementary and Alternative Medicine
on cellular signaling pathways and sensitize prostate cancer
cells to TRAIL-induced apoptosis. Our ﬁndings suggest that
the modulation of TRAIL apoptosis pathway may have a
signiﬁcant potential for prostate cancer chemoprevention,
and the overcome of TRAIL-resistance by propolis and
its phenolic components may be one of the mechanisms
responsible for their cancer preventive eﬀects. The obtained
resultsconﬁrmed thesigniﬁcance ofEEP anditscomponents
in chemoprevention of prostate cancer cells. EEP as a dietary
supplement may be useful in chemopreventionagent against
prostate cancer.
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